Amgen (AMGN) Stock Could Be 34% Below Fair Value Following Raised Guidance

Amgen has been a strong performer in large-cap biotech, and with the stock recently around US$460 per share the key question for you is how well that price lines up with the cash the business can generate over time.

• Over the past 5 years, Amgen has delivered a return of about 154.5%, which puts a lot of expectations about future cash generation and durability of its drug portfolio into the current share price.
• Recent product updates, including strong commercial traction in cardiovascular and autoimmune therapies and promising oncology trial results, can influence how steady and sizable Amgen's future cash flows may be.
• If you'd rather focus on earnings, this one's for you. See what Amgen's 26.5x P/E says about the price.

For investors, the debate is whether Amgen's current share price is adequately supported by the cash flows implied by its Discounted Cash Flow (DCF) intrinsic value estimate.

If you are weighing Amgen against other cash generative large caps, it can help to compare it with companies that pass a similar quality filter using 39 high quality undervalued stocks

Is Amgen a Bargain on Cash Flow?

The Discounted Cash Flow (DCF) approach here looks at the cash Amgen can return to shareholders over time and discounts it back to today. On this model, the latest twelve month free cash flow sits at about $10.2b, with forecasts pointing to recovering and then growing free cash flows over the coming decade in dollar terms, rather than one peak year followed by a steep drop. That pattern fits a mature biotech that still has meaningful products and pipeline assets contributing to owner earnings.

The projections imply that this cash generation profile supports an estimated intrinsic worth that sits substantially above the current share price of $460.42. Because Amgen recently reported higher full year guidance on the back of strong Q3 2026 product sales and clinical progress, the raised outlook helps explain why a cash flow based model can still justify a richer valuation than the equity market is currently assigning. Find out what Amgen could be worth using our Discounted Cash Flow (DCF) estimate.

The Amgen Narrative: What Would Justify Today's Price?

Narratives pick up where the DCF puzzle leaves off for Amgen and spell out which paths for revenue, margins and earnings would need to play out for the shares to look meaningfully higher or lower than today’s price on Simply Wall St’s Community page. Each one treats Amgen's implied value as a concrete, testable thesis about the business that you can watch over time, instead of a one off snapshot.

Community views on Amgen split between those who see a broad growth engine and those who think the dividend story is already fully priced in.

Bull case: 14% undervalued

"The breadth of Amgen's double digit volume growth now extends across 22 products that each delivered double digit sales growth in the latest quarter..."

Discover why this Narrative puts Amgen at 14% undervalued.

Bear case: 44% overvalued

"Thesis: 5-7% dividend growth is realistic, but the current price already reflects it (yield well below the 5-year average)..."

Explore why this Narrative puts Amgen at 44% overvalued.

For Amgen, who is steering the ship and how are they rewarded?

Valuation only tells you what the market is pricing in today. The real signal often comes from who runs Amgen, how their incentives are wired and whether that pay structure truly aligns with shareholders. See who runs Amgen and how they are paid.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com